Transfusion-induced HLA sensitization in wait-list patients and kidney transplant recipients
Kidney International · 2024-11 · 106 (5) · 795-805
DOI: 10.1016/j.kint.2024.07.030 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Kidney International, 2024-11. Verfasst von Michelle Willicombe und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, UK; Imperial College Renal and Transplan…. Hauptthemen laut MEDLINE: Kidney Transplantation, Waiting Lists, HLA Antigens. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research, Imperial College Healthcare NHS Trust.
Abstract (Originalsprache)
Human leukocyte antigen (HLA) sensitization remains an impediment to successful solid organ transplantation, whether it be chances of receiving a transplant offer or subsequent transplant longevity. Current treatments targeting HLA antibodies lack long-term effectiveness; therefore, preventing HLA sensitization should remain a priority in all potential wait-list candidates and transplant recipients. Recent advances in the management of anemia in patients with chronic kidney disease may reduce the need for red cell transfusions. However, data from several anemia intervention studies of novel therapeutic agents have shown that a need for transfusion will remain. It has also been increasingly recognized that blood transfusions following kidney transplantation, especially in the peri-operative period, are common. Routine data on transfusion incidence, indications, and outcomes are not captured by most kidney and transplant registries across the globe. This restricts the evidence to inform both clinicians and patients on the clinical effects of transfusion, which have been considered both an allogeneic stimulus and to be immunomodulatory.This review aims to provide an update on what is currently known about transfusion-induced HLA sensitization in wait-list candidates and transplant recipients, summarizes where evidence is lacking, and demonstrates the distinct need for patient blood management guidelines in the field of kidney transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, UK; Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital,…
- Biomedical Research Centre Haematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; NHS Blood and Transplant, John Radcliffe Hospital, Oxford, UK.
Förderung
- National Institute for Health and Care Research
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- Imperial College Healthcare NHS Trust
- Imperial College London
Zitieren
APA
Willicombe, M., & Roberts, D. J. (2024). Transfusion-induced HLA sensitization in wait-list patients and kidney transplant recipients. Kidney International, 106(5), 795-805. https://doi.org/10.1016/j.kint.2024.07.030
Vancouver
Willicombe M, Roberts DJ. Transfusion-induced HLA sensitization in wait-list patients and kidney transplant recipients. Kidney International. 2024;106(5):795-805. doi:10.1016/j.kint.2024.07.030
BibTeX
@article{Willicombe2024,
author = {Willicombe, Michelle and Roberts, David J},
title = {Transfusion-induced HLA sensitization in wait-list patients and kidney transplant recipients},
journal = {Kidney International},
year = {2024},
volume = {106},
number = {5},
pages = {795--805},
doi = {10.1016/j.kint.2024.07.030}
}
EUVIMED